388 related articles for article (PubMed ID: 24108703)
1. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
2. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
3. The role of gamma delta T cells in haematopoietic stem cell transplantation.
Minculescu L; Sengeløv H
Scand J Immunol; 2015 Jun; 81(6):459-68. PubMed ID: 25753378
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
5. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
6. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
[TBL] [Abstract][Full Text] [Related]
7. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
Pistoia V; Tumino N; Vacca P; Veneziani I; Moretta A; Locatelli F; Moretta L
Front Immunol; 2018; 9():984. PubMed ID: 29867961
[TBL] [Abstract][Full Text] [Related]
8. Human NK receptors: from the molecules to the therapy of high risk leukemias.
Moretta L; Locatelli F; Pende D; Sivori S; Falco M; Bottino C; Mingari MC; Moretta A
FEBS Lett; 2011 Jun; 585(11):1563-7. PubMed ID: 21554879
[TBL] [Abstract][Full Text] [Related]
9. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
10. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
[TBL] [Abstract][Full Text] [Related]
11. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
12. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
13. The potential role of γδ T cells after allogeneic HCT for leukemia.
Handgretinger R; Schilbach K
Blood; 2018 Mar; 131(10):1063-1072. PubMed ID: 29358176
[TBL] [Abstract][Full Text] [Related]
14. Alloreactive natural killer cells in targeting high-risk leukaemias.
Moretta L; Locatelli F; Moretta A
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii39-43. PubMed ID: 19022812
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Haematopoietic Stem Cell Transplantation: Role of NK Cells and Effect of Cytomegalovirus Infections.
Della Chiesa M; Moretta L; Muccio L; Bertaina A; Moretta F; Locatelli F; Moretta A
Curr Top Microbiol Immunol; 2016; 395():209-24. PubMed ID: 26160014
[TBL] [Abstract][Full Text] [Related]
16. Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias.
Moretta L; Locatelli F; Pende D; Mingari MC; Moretta A
Tissue Antigens; 2010 Feb; 75(2):103-9. PubMed ID: 20002610
[TBL] [Abstract][Full Text] [Related]
17. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.
Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E
Front Immunol; 2021; 12():625165. PubMed ID: 33777007
[TBL] [Abstract][Full Text] [Related]
19. NK cell receptors and their ligands in leukemia.
Verheyden S; Demanet C
Leukemia; 2008 Feb; 22(2):249-57. PubMed ID: 18046448
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
